CrunchBase is hiring! Check out our open positions →
Register | Login or Login

General Information

Websiteeastoncapital.com
Phone212 702 0950
Emailinfo@eastoncapita...
Employees
Founded1999
DescriptionInvestment Group

Funds

Offices

HQ
767 Third Avenue (at 48th Street)
7th Floor
New York, NY, 10017
USA
Florida Office
520 Alhambra Circle
Coral Gables, FL, 33134
USA

People

Former People

Tags

Easton Capital

Easton Capital Investment Group manages approximately $200 million on behalf of a number of significant institutional investors in its three funds, Easton Capital Partners, L.P., Easton Hunt Capital Partners, L.P. and Easton Hunt New York LP. Easton makes investments ranging in size from $2 million to $7.5 million and has strategic co-investment relationships with many of its institutional investors which allow it to participate in larger initial and follow-on rounds of funding. Easton has offices in New York and Florida.

Recent Milestones

Investments

Company Date Round Size Participants
Medikly 2/13Series A$1.2M1
Within3 12/12Venture Round2
Resolve Therapeutics 11/12Series B$5.8M3
Promedior 3/12Series D$21.5M6
TigerText 2/12Series B$8.2M2
Resolve Therapeutics 5/11Series A$2M2
bluebird bio 4/11Venture Round$30M5
Format Dynamics 6/10Series B$5.5M1
bluebird bio 3/10Series B$35M5
Coapt Systems 12/09Debt$3.72M8
CardioMEMS 10/09Series F$22.1M10
PlaySpan 11/08Series B$16.8M4
Achronix Semiconductor 10/08Series B$52M5
PlaySpan 7/08Venture Round$5M4
GoCrossCampus 9/07Seed$375k2
PlaySpan 9/07Series A$6.5M4
IGA Worldwide 7/07Series B$25M6
Gentis 6/07Series A$10M4
Biolex Therapeutics 5/07Series C$30M9
Coapt Systems 3/07Series E$22.6M7
Sanarus Medical 2/07Series E$15M6
Trellis Bioscience 2/07Series B$10M4
Achronix Semiconductor 1/07Series A$25.4M4
Promedior 5/06Series A$14M5
IGA Worldwide 2/06Series A$17M3
Sonics 12/05Series D$12M5

Videos

Sources

    IGA Worldwide Completes "Significant" Investment Round (finsmes.com) [edit]
  1. New York’s Medikly Inks $1.2M (pehub.com) [edit]
  2. Within3 Announces New Round of Funding (reuters.com) [edit]
  3. Resolve Therapeutics Raises $5.8M in Series B Financing (finsmes.com) [edit]
  4. Promedior lands $21.5M D round for fibrosis pipeline (fiercebiotech.com) [edit]
  5. TigerText Completes $8.2m Second Funding (finsmes.com) [edit]
  6. Resolve Therapeutics Raises $2M in Series A Financing (finsmes.com) [edit]
  7. bluebird bio Secures Additional $30 Million in Financing; ARCH Venture Partners Joins Investor Team (live-pr.com) [edit]
  8. Format Dynamics Secures Series B Financing (businesswire.com) [edit]
  9. Genetix raises $35M to advance gene therapies (fiercebiotech.com) [edit]
  10. Coapt Systems takes $3.7M for facial rejuvenation (deals.venturebeat.com) [edit]
  11. CardioMEMS, Inc.: Series F $22.1M (onbiovc.com) [edit]
  12. TechCrunch (techcrunch.com) [edit]
  13. Achronix Completes First Close of $52 Million Series B Preferred Stock Financing (achronix.com) [edit]
  14. PlaySpan Plays With $5 Million Venture Capital (venturedeal.com) [edit]
  15. Storming the Campuses (nytimes.com) [edit]
  16. techcrunch.com [edit]
  17. igaworldwide.com [edit]
  18. Gentis raises $10M for spine-injected implants (venturebeat.com) [edit]
  19. BIOLEX THERAPEUTICS RAISES $30 MILLION TO ADVANCE ITS HEPATITIS C DRUG CANDIDATE AND OTHER PIPELINE PROGRAMS (biolex.com) [edit]
  20. Coapt Systems, maker of aesthetic surgery implants, raises $22.6M more (deals.venturebeat.com) [edit]
  21. Sanuras, breat tumor device company raises $15M (deals.venturebeat.com) [edit]
  22. Trellis Bioscience, cell monitoring company, raises $10M (deals.venturebeat.com) [edit]
  23. Achronix Completes $25.4 Million Series A Preferred Stock Financing (prnewswire.com) [edit]
  24. EDGAR [edit]
  25. igaworldwide.com [edit]
  26. EDGAR [edit]
Edit This Page
Last Edited 4/30/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

Recent Incoming Links

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy